

BIOGRAPHICAL SKETCH

Provide the following information for the Senior/key personnel and other significant contributors in the order listed on Form Page 2. Follow this format for each person. **DO NOT EXCEED FOUR PAGES.**

| | | | |
|---|---------------------------|---|----------------------------|
| NAME Glenn Morris Mills, MD | | POSITION TITLE | |
| eRA COMMONS USER NAME (credential, e.g., agency login) gmmills | | Professor of Medicine MB-CCOP Principal Investigator | |
| EDUCATION/TRAINING (Begin with baccalaureate or other initial professional education, such as nursing, include postdoctoral training and residency training if applicable.) | | | |
| INSTITUTION AND LOCATION | DEGREE (if applicable) | MM/YY | FIELD OF STUDY |
| Millsaps College, Jackson, Mississippi | | 05/71 | Chemistry |
| University of Mississippi Medical Center, Jackson, MS | MD | 12/74 | Internal Medicine |
| Tripler Army Medical Center, Honolulu, Hawaii | Postdoctoral | 06/76 | Internal Medicine |
| Brooke Army Medical Center, Fort Sam Houston, TX | Fellowship | 06/80 | Hematology/Oncology |

A. Personal Statement

As Director of the Feist-Weiller Cancer Center, Professor and Vice Chairman of the Department of Medicine, Chief of Hematology and Medical Oncology, Director of Clinical Research and Program Director of the Hematology and Medical Oncology fellowship program at LSU Health Sciences Center – Shreveport (LSUHSC-S), I feel I am uniquely qualified to sit on the executive committee and be a site leader for our Shreveport component and sub-components for the Gulf South-Minority Based NCORP (GS-MB-NCORP). The overall goal of the GS-MB-NCORP is to decrease cancer incidence and deaths among the minorities throughout the state of Louisiana through participation in clinical research trials with an emphasis on cancer control and prevention. I have the expertise and experience in clinical research to aide in achieving the goals of the GS-MB-NCORP. I have been the LSUHSC-Shreveport MBCCOP Principal Investigator since the inception of the program in 2007. I have been the SWOG Principal Investigator for LSUSHC-Shreveport since 1986, and our site has received recognition from SWOG as a top accruing minority site as well as for the quality of our data. I have been a member of the Hematology/Oncology faculty at LSUHSC-S since 1986 and Director of Clinical Research at Feist Weiller Cancer Center since 2001. Under my direction and the support and participation of medical hematologist/oncologists, we have been successful in building a clinical research program dedicated to patient enrollment and strict compliance with federal regulatory guidelines. Successful collaboration with a comprehensive multi-disciplinary group of specialists who assist in identifying enrolling, and treating study patients is a major part of the strength and success of our program. I maintain strong ties with other oncologists and physicians in the community, as well as throughout the state, including Dr. Augusto Ochoa. As well, through regular attendance at cooperative group, NCI CCOP, and research base meetings, I have developed good relationships and channels of communication with the leaders in the NCORP program. I feel that by joining forces with the LSUHSC-New Orleans MB-CCOP as well as the Mary Bird Perkins NCI Community Cancer Center Program, we can drastically increase enrollments of our patient population into NCI clinical trials.

B. Positions and Honors

Positions and Employment

- 1986-1992 *Assistant Professor of Medicine, Section of Hematology/Oncology, LSU School of Medicine, Shreveport, Louisiana*
- 1989–1992 *Director, Hematology/Oncology Fellowship Program Feist-Weiller Cancer Center, LSU School of Medicine-Shreveport*
- 7/1992-6/2000 *Associate Professor of Medicine, Section of Hematology/Oncology, LSU Health Sciences Center, Shreveport, Louisiana July 1992 – June 2000*

Program Director/Principal Investigator (Last, First, Middle): Ochoa, Augusto C.

7/1999-1/2000 *Acting Chief*, Hematology/Oncology Section, LSU Health Sciences Center, Shreveport, Louisiana
7/1999-1/2000 *Director, Hematology/Oncology Fellowship Program* Feist-Weiller Cancer Center, LSU School of Medicine-Shreveport
1997 to 2011 *Associate Director*, Feist-Weiller Cancer Center LSU Health Sciences Center, Shreveport, Louisiana
1988 – Present *Consultant, Hematology/Oncology Service*, Overton Brooks VA Medical Center, Shreveport, LA 71101
7/2000-Present *Professor of Medicine*, Section of Hematology/Oncology, LSUHSC-Shreveport, Shreveport, Louisiana
4/2001–Present *Vice Chairman, Department of Medicine* LSUHSC-Shreveport, Shreveport, Louisiana
1995 – 2012 *Director of Clinical Research*, Feist-Weiller Cancer Center LSUHSC-Shreveport
2012 – Present *Director*, Feist-Weiller Cancer Center LSU Health Sciences Center, Shreveport, Louisiana

Other Experience and Professional Memberships

AOA, 1974 - Present

Assistant Investigator, Polycythemia Vera Study Group, New York, New York, 1980 - 1981

Southwest Oncology Group, Principal Investigator 1980 – Present

SWOG Committee Memberships:

Leukemia Committee, 1980 – Present

Leukemia Pathology Review, 1988 - Present

Lung Committee, 1986 - Present

Quality Assurance Auditor 1982 – Present

GI Committee, 1998 to present

Head and Neck Committee, 1998 to 2006.

Cancer Control Committee, 1998 to present

Lymphoma Committee, 1985 – 2002

Member, American Association for the Advancement of Science, 1980 - Present

Member, American Society of Hematology, 1981 - Present

Member, American Federation for Clinical Research 1981 - Present

President, San Antonio Blood Club, 1985

Member, American Society of Clinical Oncology, 1986 - Present

Member, Southern Medical Association, 1988 - Present

Member, Southern Oncology Association, 1988 - Present

Member, Louisiana State Medical Society, 1992 – Present

Member, Caddo Parish Medical Society, 1992 – Present

Member AMA, 1992 to present.

Member, Association of Program Directors in Internal Medicine, 1992-1997

Member, American Association of Cancer Research, 1994-Present

Member, Association of Patient Oriented Research, 2000

Member, Association of Subspecialty Professors of Medicine, 1999 to present.

Member, International Society of Lung Cancer, 1999 to present.

Member Association of Community Cancer Centers, 1999 to present.

Member NCI Clinical Trials Support Unit, 2000

Member **ACGME** Residency Review Committee in Internal Medicine Appointed 1/1/2003-present;

Executive Committee 2004 - present

Member, Coalition For a Tobacco Free Louisiana, 2002 to present

Medical Director, Northwest Louisiana Tumor Registry, 1987 – 1988 & 1999 to 2001

Member, Louisiana State Hemophilia Advisory Committee, 1989 - 1992

Board of Directors, Northwest Louisiana Chapter of the American Cancer Society, 1990 - 1992

Member, Louisiana Lung and Cancer Trust Fund Board, 1990 - 1995

Treasurer, Louisiana Lung and Cancer Trust Fund Board, 1992 - 1995

Grant Review Committee for LSUMC-NO Center for Excellence in Cancer, 1995

C. Selected Peer-reviewed Publications

1. Adelstein DJ, Moon J, Hanna E, Giri PG, **Mills GM**, Wolf GT, Urba SG. Docetaxel, cisplatin, and fluorouracil induction chemotherapy followed by accelerated fractionation/concomitant boost radiation and concurrent cisplatin in patients with advanced squamous cell head and neck cancer: A Southwest Oncology Group phase II trial (S0216). *Head Neck*. 2010 Feb;32(2):221-8.
2. Sequist LV, Fidias PM, Temel JS, Kolevska T, Rabin MS, Boccia RV, Burris HA, Belt RJ, Huberman MS, Melnyk O, **Mills GM**, Englund CW, Caldwell DC, Keck JG, Meng L, Jones M, Brown GL, Edelman MJ, Lynch TJ. Phase 1-2a multicenter dose-ranging study of canfosfamide in combination with carboplatin and paclitaxel as first-line therapy for patients with advanced non-small cell lung cancer. *J Thorac Oncol*. 2009 Nov;4(11):1389-96.
3. Ampil F, Sangster G, **Mills G**, Nathan CO, Lian T, Hall A. Radiologic findings after successful chemoradiation for nasopharyngeal cancer with skull base erosion. *Ear Nose Throat J*. 2010 Jan;89(1):38-41.
4. Ekshyyan O, **Mills GM**, Lian T, Amirghahari N, Rong X, Lowery-Nordberg M, Abreo F, Veillon DM, Caldito G, Speicher L, Glass J, Nathan CO. Pharmacodynamic evaluation of temsirolimus in patients with newly diagnosed advanced-stage head and neck squamous cell carcinoma. *Head Neck*. 2010 Dec;32(12):1619-28.
5. Peddi P, Slay LE, Lillen DL, Fowler MR, Cotelingam J, Veillon DM, Ayirookuzhi S, Koshy N, **Mills GM**, Munker R. Metastatic malignant melanoma in a patient with Hodgkin's lymphoma in remission. *J La State Med Soc*. 2010 Jan-Feb;162(1):47-50.
6. Chu DZ, Hussey MA, Alberts DS, Meyskens FL Jr, Fenoglio-Preiser CM, Rivkin SE, **Mills GM**, Giguere JK, Blanke CD, Goodman GE. Colorectal Chemoprevention Pilot Study (SWOG-9041), randomized and placebo controlled: the importance of multiple luminal lesions. *Clin Colorectal Cancer*. 2011 Dec;10(4):310-6.
7. Armaghany T, Wilson JD, Chu Q, **Mills G**. Genetic alterations in colorectal cancer. *Gastrointest Cancer Res*. 2012 Jan;5(1):19-27. PMC3348713.
8. Ampil FL, Caldito G, **Mills G**, Marion J, Balandin A, Ponugupati J. Short survival after palliative radiotherapy for brain metastases in lung cancer: does the end justify the means? *Am J Hosp Palliat Care*. 2013 Jun;30(4):331-3.
9. Ampil F, Caldito G, **Mills G**, Takalkar A, Ghali G, Kim D. Chemoradiotherapy for unresectable stage IVB head and neck cancer. *J La State Med Soc*. 2012 Sep-Oct;164(5):260-4.
10. Jafri SH, **Mills G**. Lifestyle modification in colorectal cancer patients: an integrative oncology approach. *Future Oncol*. 2013 Feb;9(2):207-18.
11. Ampil F, Chaudhery S, Devarakonda S, **Mills G**. Extended survival after chemotherapy and conservative radiotherapy for HPV-16 positive stage IVB oropharyngeal carcinoma. *Acta Oncol*. 2013 Aug;52(6):1236-7.
12. Jafri SH, Shi R, **Mills G**. Advance lung cancer inflammation index (ALI) at diagnosis is a prognostic marker in patients with metastatic non-small cell lung cancer (NSCLC): a retrospective review. *BMC Cancer*. 2013 Mar 27;13:158. PMC3618002.
13. Eberhardt WE, Mitchell P, Schiller JH, Brown MP, Thomas M, **Mills G**, Jehl V, Urva SR, De Leo JJ, Gogov S, Papadimitrakopoulou V. Feasibility of adding everolimus to carboplatin and paclitaxel, with or without bevacizumab, for treatment-naive, advanced non-small cell lung cancer. *Invest New Drugs*. 2013 Apr 12. [Epub ahead of print]
14. Shi R, **Mills G**, McLarty J, Burton G, Shi Z, Glass J. Commercial insurance triples chances of breast cancer survival in a public hospital. *Breast J*. 2013 Nov-Dec;19(6):664-7. [PubMed - in process]
15. Stiff PJ, Unger JM, Cook JR, Constine LS, Couban S, Stewart DA, Shea TC, Porcu P, Winter JN, Kahl BS, Miller TP, Tubbs RR, Marcellus D, Friedberg JW, Barton KP, **Mills GM**, LeBlanc M, Rimsza LM,

Program Director/Principal Investigator (Last, First, Middle): Ochoa, Augusto C.
Forman SJ, Fisher RI. Autologous transplantation as consolidation for aggressive non-Hodgkin's lymphoma. N Engl J Med. 2013 Oct 31;369(18):1681-90.

D. Research Support

GLENN M. MILLS, MD **ACTIVE**

U10CA128567

08/01/2007-05/31/2015

NIH-NCI

LSUHSC-Shreveport Feist Weiller Cancer Center MBCCOP

The Feist-Weiller Cancer Center (FWCC) Minority-Based Community Clinical Oncology Program (MB-CCOP) aims to provide increased access to state-of-the-art cancer prevention care, and control through NCI-sponsored clinical trials to the minority and indigent populations in the northwestern section of La., and throughout the state of Louisiana.

Role: Principal Investigator

Cephalon – Protocol #C18083/3064/NL/MN

08/2009 – 03/2017

CEPHALON Oncology

An Open-Label, Randomized, Parallel-Group Study of Bendamustine Hydrochloride and Rituximab (BR) Compared With Rituximab, Cyclophosphamide, Vincristine, and Prednisone (R-CVP) or Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in the First-Line Treatment of Patients with Advanced Indolent Non-Hodgkin's Lymphoma (NHL) or Mantle Cell Lymphoma (MCL)

The major goal of this project is to compare the complete response rate of bendamustine and rituximab with that of standard treatment regimens of either rituximab, cyclophosphamide, vincristine and prednisone, or rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone in the first-line treatment of patients with advanced indolent NHL or mantle cell lymphoma on the basis of a non-inferiority margin of 15%.

Panorama 1 – Protocol #CLBH589D2308

12/2009 – 06/2014

NOVARTIS

A Multicenter, Randomized, Double-Blind, Placebo Controlled Phase 3 Study of Panobinostat in Combination with Bortezomib and Dexamethasone in Patients with Relapsed Multiple Myeloma.

It is the purpose of this study to compare treatment with BTZ/Dex + PAN to BTZ/Dex + Placebo in patients with previously treatment MM whose disease has recurred or progressed. Progression free survival is the primary endpoint of the study.

Completed Research Support

Wyeth 3066KI-404-WW

02/25/2008 – 03/01/2012

WYETH Pharmaceuticals

“A Randomized Trial of Temsirolimus and Sorafenib as Second-Line Therapy in Patients with Advanced Renal Cell Carcinoma Who Have Failed First-Line Sunitinib Therapy”

The major goals of this project are to compare the efficacy, safety and tolerability of temsirolimus and sorafenib when used as single agents in the second-line setting in subjects with advanced RCC who have failed first-line treatment with sunitinib.

Amgen 20062088

11/26/2007 – 12/01/2012

AMGEN Pharmaceutical Co.

“Phase II, Single-Arm, Open-Label, Multi-center Trial of Second-Line Panitumumab Monotherapy in Patients with Metastatic or Recurrent Squamous Cell Carcinoma of the Head and Neck”

The major goal of this project is to estimate the effect of second-line panitumumab monotherapy on objective response rate in patients with metastatic or recurrent squamous cell carcinoma of the head and

Program Director/Principal Investigator (Last, First, Middle): Ochoa, Augusto C.

neck. Time to response, duration of response, rate of disease control, time to progression, PFS, and OS will also be assessed.